Avadel Pharmaceuticals Q2 2024 Adj EPS $(0.14) Beats $(0.16) Estimate, Sales $41.50M Beat $37.53M Estimate
Portfolio Pulse from Benzinga Newsdesk
Avadel Pharmaceuticals (NASDAQ: AVDL) reported Q2 2024 adjusted EPS of $(0.14), beating the $(0.16) estimate. Sales were $41.50M, surpassing the $37.53M estimate and marking a 2.67K% increase from the same period last year.
August 08, 2024 | 11:10 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Avadel Pharmaceuticals reported better-than-expected Q2 2024 results with an adjusted EPS of $(0.14) and sales of $41.50M, significantly beating analyst estimates and showing a massive year-over-year sales increase.
The better-than-expected EPS and sales figures, along with a significant year-over-year sales increase, are likely to positively impact AVDL's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100